Docoh
Loading...

PGNY Progyny

News

From Benzinga Pro
Why Jim Cramer Likes Progyny
19 Nov 21
Long Ideas, Media, Trading Ideas
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Lemonade, Inc. (NYSE: LMND) is down so low. He recommends holding onto the stock for a little bit more time.
Progyny: Q3 Earnings Insights
4 Nov 21
Earnings
Progyny (NASDAQ:PGNY) reported its Q3 earnings results on Thursday, November 4, 2021 at 04:05 PM. Here's what investors need to know about the announcement.
Progyny Q3 EPS $0.17 Beats $0.06 Estimate, Sales $122.30M Miss $125.45M Estimate
4 Nov 21
Earnings, News
Progyny (NASDAQ:PGNY) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.06 by 183.33 percent. This is a 240 percent increase over earnings of $0.05 per share from the same
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Nov 21
Movers
Gainers
Earnings Scheduled For November 4, 2021
4 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
Where Progyny Stands With Analysts
30 Sep 21
Analyst Ratings
Progyny (NASDAQ:PGNY) has observed the following analyst ratings within the last quarter:
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
30 Sep 21
Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings
Upgrades
Berenberg Initiates Coverage On Progyny with Buy Rating, Announces Price Target of $81
30 Sep 21
News, Price Target, Initiation, Analyst Ratings
Berenberg initiates coverage on Progyny (NASDAQ:PGNY) with a Buy rating and announces Price Target of $81.
EVP And General Counsel Of Progyny Trades $1.85 Million In Company Stock
29 Sep 21
News, Insider Trades, Trading Ideas
Jennifer Bealer, EVP And General Counsel at Progyny (NASDAQ:PGNY), made a large buy and sell of company shares on September 24, according to a new SEC filing.
Barclays Maintains Overweight on Progyny, Raises Price Target to $80
28 Sep 21
News, Price Target, Analyst Ratings
Barclays analyst Sarah James maintains Progyny (NASDAQ:PGNY) with a Overweight and raises the price target from $72 to $80.